CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade - Summary - MDSpire

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

  • By

  • Ieva Ailte

  • Sudhir Kumar Chauhan

  • Lina Prasmickaite

  • Assia V. Bassarova

  • Amanda Poissonnier

  • Marike Feenstra

  • Marta Nyakas

  • Bjarne Johannessen

  • Truls Ryder

  • Robert Hermann

  • Lars Frich

  • Arild Holth

  • Else Marit Inderberg

  • Henrik Jespersen

  • Vivi Ann Flørenes

  • Jon Amund Kyte

  • Gunhild M. Mælandsmo

  • Eivind Valen Egeland

  • May 4, 2026

  • 0 min

Share

Objective:

To explore the cellular composition of regional lymph nodes in stage III melanoma patients and identify potential prognostic biomarkers associated with outcomes following adjuvant PD-1 therapy, which could enhance patient selection and treatment strategies.

Key Findings:
  • Higher proportions of CD103+PD-1+CD8+ T cells and plasmablast-like CD38hiCD19dim cells correlate with improved prognosis, suggesting potential targets for therapeutic intervention.
  • A 'B cell excluded' subgroup in untreated patients showed worse outcomes, with reduced B cell scores and lower activation gene expression, indicating a need for tailored treatment approaches.
Interpretation:

The presence of specific immune cell populations in lymph nodes is strongly linked to better survival outcomes in stage III melanoma patients treated with PD-1 inhibitors, suggesting their potential as biomarkers for guiding treatment decisions.

Limitations:
  • Small sample size of the study cohort may limit generalizability and the ability to draw broad conclusions.
  • The study primarily focuses on lymph node samples, which may not fully represent systemic immune responses, potentially overlooking other relevant factors.
Conclusion:

Baseline infiltration of CD8+ TRM and plasmablast-like CD38hiCD19dim cells in regional lymph nodes is a promising prognostic indicator for distant metastasis-free survival in stage III melanoma patients receiving anti-PD-1 therapy.

Original Source(s)

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

  • by Ieva Ailte, Sudhir Kumar Chauhan, Lina Prasmickaite, Assia V. Bassarova, Amanda Poissonnier, Marike Feenstra, Marta Nyakas, Bjarne Johannessen, Truls Ryder, Robert Hermann, Lars Frich, Arild Holth, Else Marit Inderberg, Henrik Jespersen, Vivi Ann Flørenes, Jon Amund Kyte, Gunhild M. Mælandsmo, Eivind Valen Egeland

  • May 4, 2026

Related Content

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review